Investing.com - Genmab AS reported on Wednesday first quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Genmab AS announced earnings per share of kr0.1 on revenue of kr300.45M. Analysts polled by Investing.com anticipated EPS of kr0.0765 on revenue of kr301.14M.
Genmab AS shares are down 32% from the beginning of the year and are trading at kr27.98 , down-from-52-week-high.They are under-performing the S&P 500 which is down 17.4% from the start of the year.
Genmab AS follows other major Healthcare sector earnings this month
Genmab AS's report follows an earnings beat by J&J on April 19, who reported EPS of kr2.67 on revenue of kr23.43B, compared to forecasts EPS of kr2.59 on revenue of kr23.62B.
UnitedHealth had beat expectations on April 14 with first quarter EPS of kr5.49 on revenue of kr80.15B, compared to forecast for EPS of kr5.36 on revenue of kr78.73B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar